Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 62 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Acute Toxic Leukoencephalopathy: Etiologies, Imaging Findings, and Outcomes in 101 Patients
AJNR 40:267-275, Ozutemiz, C.,et al, 2019

Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018

Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018

Metronidazole-Associated Encephalopathy
NEJM 374:1465, Baden, L.R., 2016

Risk Factors of Hyperammonemia in Patients with Epilepsy Under Valproic Acid Therapy
Medicine 93:e66, Tseng, Y.L.,et al, 2014

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012

Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011

HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
NEJM 364:1134-1143, McCormack,M.,et al, 2011

HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
NEJM 364:1126-1133, Chen,P.,et al, 2011

Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010

Rifaximin Treatment in Hepatic Encephalopathy
NEJM 362:1071-1081, 1140, Bass,N.M.,et al, 2010

An Effective Immunotherapy Regimen for VGKC Antibody-Positive Limbic Encephalitis
JNNP 81:1167-1169, Wong,S.H.,et al, 2010

Acute Hepatic Encephalopathy: Diffusion-Weighted and Fluid-Attenuated Inversion Recovery Findings, and Correlation With Plasma Ammonia Level and Clinical Outcome
AJNR 31:1471-1479, McKinney,A.M.,et al, 2010

Levetiracetam as a Possible Cause of Fulminant Liver Failure
Neurol 71:685-686, Tan,T.C.H.,et al., 2008

Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007

Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trial
Stroke 38:2965-2971, Ford,G.A.,et al, 2007

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006

An Acute, Life-Threatening, Hypersensitivity Reaction to Riluzole
Neurol 67:2260-2261, Sorenson,E.J.,et al, 2006

Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005

Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005

The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004

Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004

Valproate Therapy and Nonalcoholic Fatty Liver Disease
Ann Neurol 55:729-732, Luef,G.J.,et al, 2004

Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate, III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Arch Neurol 60:379-385, Brewer,G.J.,et al, 2003

Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002

Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001

Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000

Agranulocytosis Associated with Lamotrigine
BMJ 318:1179, DeCamargo,O.A.K., 1999

Reye's Syndrome in the United States from 1981 Through 1997
NEJM 340:1377-1382,1423, Belay,E.D.,et al, 1999

Multisystem Hypersensitivity Reaction to Lamotrigine
Neurol 53:1367, Sarris,B.M.&Wong,J.G., 1999

Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999

Interferon Treatment for Multiple Sclerosis:Autoimmune Complications May be Lethal
Neurol 50:570-571, Durelli,L.,et al, 1998

HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998

Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998

Medical Causes of Seizures
Lancet 352:383-390, Delanty,N.,et al, 1998

Lamotrigine-Associated Anticonvulsant Hypersentivitiy Syndrome
Neurol 51:1171-1175, Schlienger,R.G.,et al, 1998

Tasmar (tolcapone) Labeling Revisions of Package Insert
Roche Laboratories, , 1998

Seizures in Medically Complex Patients
Epilepsia 38:S55-S59, Boggs,J.G., 1997

Complications of Intravenous Gammaglobulin in Neuromuscular and other Disease
Muscle & Nerve 19:388-391996., Bertorini,T.E.,et al, 1996

Valproic Acid Hepatic Fatalities. III. U. S. Experience Since 1986
Neurol 46:465-469, Bryant,A.E.&Dreifuss,F., 1996

Felbamate-Associated Fatal Acute Hepatic Necrosis
Neurol 46:1457-1459, O'Neil,M.G.,et al, 1996

Riluzole
Lancet 348:795-799, Wokke,J., 1996

Fulminant Hepatic Failure Induced by Lamotrigine
BMJ 311:292, Makin,A.J.,et al, 1995

Carbamazepine Hypersensitivity Syndrome:Report of 4 Cases & Review of Literature
Medicine 74:144-151, DeVriese,A.S.P.,et al, 1995

Anticonvulsant Hypersensitivity Syndrome
Arch Int Med 155:2285-2290, Vittorio,C.C.&Muglia,J.J., 1995

A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994

Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimer's Disease
JAMA 271:992-998, Watkins,P.B.,et al, 1994



Showing articles 0 to 50 of 62 Next >>